Cytosorbents Corporation (CTSO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

2.1300

-0.1200

(-5.33%)

At close: 04:00PM EDT

2.1300

0.00

(0.00%)

After hours:

04:01PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Engulfing Line (Bullish)

View all chart patterns

Performance Outlook

Previous Close	2.2500
Open	2.2800
Bid	2.0000 x 2900
Ask	2.1800 x 1000
Day's Range	2.1200 - 2.3200
52 Week Range	1.7800 - 9.8000
Volume	149,872
Avg. Volume	207,696

Market Cap	92.787M
Beta (5Y Monthly)	0.23
PE Ratio (TTM)	N/A
EPS (TTM)	-0.5700
Earnings Date	Aug 01, 2022 - Aug 05, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	8.83

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CTSO

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Cytosorbents Corporation
COLL: What does Argus have to say about COLL?COLLEGIUM PHARMACEUTICAL INC has an Investment Rating of SELL; a target price of $12.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
Rating
Fair Value
Economic Moat
5 days agoArgus Research

All

News

Press Releases

Research Reports

Simply Wall St.
Cytosorbents Corporation (NASDAQ:CTSO): When Will It Breakeven?
With the business potentially at an important milestone, we thought we'd take a closer look at Cytosorbents...
- Market Sentiment Around Loss-Making DoorDash, Inc. (NYSE:DASH)
  Simply Wall St.
- Breakeven Is Near for Archaea Energy Inc. (NYSE:LFG)
  Simply Wall St.
PR Newswire
CytoSorbents Reports First Quarter 2022 Results and Revises 2022 Outlook
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today reported unaudited financial and operating results for the quarter ended March 31, 2022.
PR Newswire
CytoSorbents Awarded Preferred Supplier Agreement with Asklepios, One of the Largest Private Hospital Operators in Germany
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced that the Company has been awarded a new preferred supplier agreement for CytoSorb® with the Asklepios Group (Asklepios), one of the largest private hospital operators in Germany, following the majority acquisition of RHÖN‑KLINIKUM AG in 2020.